Novavax shares are trading higher after the company announced phase 1 data from its phase 1/2 trial was well-tolerated and had a reassuring safety profile. JP Morgan also upgraded the company's from Neutral to Overweight and raised its price target from $105 to $275.

Newsletter

Subscribe to our email list for regular free market updates
as well as a chance to get coupons!